A competitive edge? TiIV binding to a bacterial transferrin (ferric-ion-binding protein, FBP; see picture, foreground) is rapid, competes with FeIII binding, and results in a short oxo–TiIV bond (EXAFS studies; see picture, background). Inhibitors of iron uptake by FBP should be active against diseases caused by bacterial pathogens. The results suggest that Ti complexes could provide such inhibition.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: